Systemic adverse events following rituximab therapy in patients with Graves’ disease

摘要: Background and aim: Rituximab (RTX) therapy has shown promising results in Graves’ disease (GD), with or without ophthalmopathy. We examined the occurrence of adverse events GD patients treated RTX. Subjects methods: Ten received RTX methimazole, while 10 methimazole only. Adverse were recorded, presence circulating immune complexes (CIC) was measured as IgG, IgM complement component 3 (C3) depositing on normal monocytes following incubation patient plasma. Results: Five had benign infusion-related at first infusion. Two developed a serum sickness-like reaction 11 days after RTX-infusion. One these diarrhea, raised orosomucoid levels, low-grade inflammation colonoscopic biopsies, iridocyclitis 1 yr later. At day 14, most pronounced immunoglobulin/C3-adherent to test monocytes, indicative CIC, observed plasma from 2 (p=0.003 p=0.01 vs asymptomatic patients). A 3rd recurrent fever symmetric polyarthritis 38, colonoscopy-verified ulcerative colitis 68. This highest increase Ig deposition by 14. The arthralgias persisted patients, despite glucocorticoid rescue therapy. Conclusions: report articular gastrointestinal symptoms out who concurrent immunosupression. joint related CIC formation.